Addition of obinutuzumab (GA101) or rituximab to chlorambucil Improves …EIN News (press release)The CLL11 trial conducted by the German CLL Study Group (GCLLSG) in collaboration with Hoffmann-La Roche for the first time compares directly the followin…
|
COMUNICADO: La adición de obinutuzumab o rituximab a clorambucil mejora …
Lainformacion.com ESTOCOLMO, June 14, 2013 /PRNewswire/ — — La adición de obinutuzumab (GA101) o rituximab a chlorambucil mejora los resultados para pacientes mayores con leucemia linfocítica crónica (CLL) y condiciones médicas coexistentes (comorbilidades) El … |
|
COMUNICADO: La adición de obinutuzumab o rituximab a clorambucil mejora …
Europa Press El ensayo CLL11 realizado por German CLL Study Group (GCLLSG) en colaboración con Hoffmann-La Roche por primera vez compara directamente los siguientes tratamientos en personas mayores con comorbilidades: GA101 más clorambucil, rituximab … |
|
XOMA Initiates Pilot Trial Studying Gevokizumab in Patients With Pyoderma …
PipelineReview.com (press release) BERKELEY, CA, USA I June 13, 2013 I XOMA Corporation (XOMA), a leader in the discovery and development of therapeutic antibodies, today announced it has opened enrollment in a pilot study to determine gevokizumab’s potential to treat acute … |
BioNews Texas |
MD Anderson Researcher Reports Idelalisib and Rituximab Produce Responses …
BioNews Texas Idelalisib Dr. Susan M. O’Brien from the University of Texas MD Anderson Cancer Center in Houston reported that pairing rituximab with the experimental agent idelalisib can improve the management of small lymphocytic lymphoma or treatment- naive … |
Immunomedics Reports Progress With Labeling Proteins, Including Antibodies …NASDAQVANCOUVER, British Columbia, June 12, 2013 (GLOBE NEWSWIRE) — Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of mon…
Immunomedics Reports Progress With Labeling Proteins, Including Antibodies …GlobeNewswire (press release)VANCOUVER, British Columbia, June 12, 2013 (GLOBE NEWSWIRE) — Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on…
|
Biogen Idec Inc. – Shareholder/Analyst Call
Seeking Alpha Daclizumab is an antibody, again, being developed for multiple sclerosis, together with our partner, AbbVie. We had one large Phase II trial for that, that read out last year that had quite positive data. There’s another Phase III trial that is fully … |
Cytarabine Improves Combination Therapy for Mantle Cell LymphomaClinical Oncology NewsFrom the Journal of Clinical Oncology. The addition of cytarabine to bendamustine plus rituximab (R-BAC) as combination therapy for older patients with mantle cell ly…
|
Do High Levels of Celiac Disease Antibodies Put Pregnant Women at Risk for …
Celiac.com Jefferson Adams is a freelance writer living in San Francisco. His poems, essays and photographs have appeared in Antioch Review, Blue Mesa Review, CALIBAN, Hayden’s Ferry Review, Huffington Post, the Mississippi Review, and Slate among others. |